ストックスクリーナーアプリを入手
10.17
2.31%
-0.24
Septerna Inc (SEPN) 最新ニュース
Novo Nordisk taps Septerna in $2.2bn deal for oral obesity therapies - MSN
Nuveen Asset Management LLC Buys New Stake in Septerna, Inc. (NASDAQ:SEPN) - Defense World
Bank of America Corp DE Makes New Investment in Septerna, Inc. (NASDAQ:SEPN) - Defense World
Septerna To Present At Jefferies Conference; SEP-631 Phase 1 Trial On Track For Q3 - Nasdaq
Deutsche Bank AG Invests $239,000 in Septerna, Inc. (NASDAQ:SEPN) - Defense World
Septerna to Present at Jefferies Global Healthcare Conference - The Manila Times
GPCR Pioneer Septerna Reveals Latest Drug Discovery Progress at Major Jefferies Healthcare Event - Stock Titan
Jane Street Group LLC Invests $600,000 in Septerna, Inc. (NASDAQ:SEPN) - Defense World
Analysts Think These Stocks Could More Than Double in Value - Investing.com
Analysts Think These Stocks Could More Than Double in Value - MarketBeat
Does Septerna, Inc. (SEPN) Have the Potential to Rally 151.27% as Wall Street Analysts Expect? - MSN
Novo Nordisk's latest bet on obesity pills: $2.2 billion for biotech Septerna - MSN
Novo Nordisk Inks $2.2B Deal With Septerna: Retail’s Thrilled - MSN
Septerna Expands Leadership with Appointment of Industry Veteran Gil Labrucherie as Chief Financial Officer - The Globe and Mail
Novo Nordisk, Septerna Agree $2.2 Billion Obesity Pill Deal - MSN
Cantor Fitzgerald Remains a Buy on Septerna, Inc. (SEPN) - The Globe and Mail
Wells Fargo & Company Boosts Septerna (NASDAQ:SEPN) Price Target to $18.00 - Defense World
Septerna First Quarter 2025 Earnings: US$0.49 loss per share (vs US$6.35 loss in 1Q 2024) - simplywall.st
22,095 Shares in Septerna, Inc. (NASDAQ:SEPN) Bought by The Manufacturers Life Insurance Company - Defense World
ETFs to Capitalize on the Novo Nordisk-Septerna Deal - MSN
Novo Nordisk in pact with Septerna for oral obesity drugs - MSN
Novo Nordisk strikes $2.2 billion deal with Septerna to develop new obesity treatments - MSN
Septerna: Novo's Investment In Incretin Program IntriguesOne For The Watchlist - Seeking Alpha
Where Septerna Stands With Analysts - Benzinga
Septerna: Deal With Novo Nordisk Is A Game Changer, While It Still Trades Well Below Net Cash - Seeking Alpha
Cantor Fitzgerald lifts Septerna stock to $25 target, maintains overweight By Investing.com - Investing.com Nigeria
Cantor Fitzgerald lifts Septerna stock to $25 target, maintains overweight - Investing.com
Novo Nordisk and Septerna enter $2.2bn cardiometabolic disease partnership - PMLiVE
Septerna price target raised to $18 from $11 at Wells Fargo - TipRanks
Novo Nordisk and Septerna Strike $2.2 Billion Deal to Develop Obesity Pills - MSN
Biotech Stocks Worth Watching – May 14th - Defense World
Septerna Highlights Business Progress and Reports First Quarter 2025 Financial Results - The Manila Times
Septerna, Inc.: Strategic Partnerships and Promising Pipeline Drive Buy Rating - TipRanks
Novo Nordisk's latest bet on obesity pills: $2.2 billion for biotech Sapterna - MSN
Septerna reports Q1 EPS (49c), consensus (45c) - TipRanks
Novo Nordisk Invests $2.2B in Septerna’s Oral Drugs - Contract Pharma
Septerna Stock Surges on Oral Obesity Drug Deal With Novo Nordisk - MSN
Novo Nordisk Inks $2.2 Billion Deal with Septerna to Advance Obesity and Diabetes Treatments - MSN
Novo Nordisk, Septerna collaborate on developing GPCR therapies - World Pharmaceutical Frontiers
Novo Nordisk Partners with Septerna for New Obesity Drug Development - GuruFocus
Novo Nordisk, Septerna Ink Up To $2.2B Obesity Drug Deal - Law360
Novo Nordisk Looks To Septerna For Oral Obesity Options - insights.citeline.com
Septerna joins a $2.2B obesity deal with Novo - BioWorld MedTech
Novo Nordisk Inks A Major Obesity Deal, Sending Shares Of New Partner Septerna Skyrocketing - Investor's Business Daily
eToro's Nasdaq debut, Exelixis outlook, Septerna–Novo deal - Yahoo Finance
Money Movers: HIT, SEPN, ALUR, LUCY, PRSO – Biotech, Healthcare, AI & Weight Loss Innovators Lead Momentum Surge – More Stocks Inside | FinancialContent - FinancialContent
1.91%
1.17%
大文字化:
|
ボリューム (24 時間):